<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Stroke</journal-id><journal-id journal-id-type="iso-abbrev">Stroke</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Stroke</journal-title></journal-title-group><issn pub-type="ppub">0039-2499</issn><issn pub-type="epub">1524-4628</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10050136</article-id><article-id pub-id-type="pmcid-ver">PMC10050136.1</article-id><article-id pub-id-type="pmcaid">10050136</article-id><article-id pub-id-type="pmcaiid">10050136</article-id><article-id pub-id-type="manuscript-id">NIHMS1876500</article-id><article-id pub-id-type="pmid">36866670</article-id><article-id pub-id-type="doi">10.1161/STROKEAHA.122.040356</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1876500</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1876500</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Cost effectiveness of smoking-cessation interventions in patients with ischemic stroke and transient ischemic attack</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Wechsler</surname><given-names initials="PM">Paul M</given-names></name><degrees>MD</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liberman</surname><given-names initials="AL">Ava L</given-names></name><degrees>MD</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Restifo</surname><given-names initials="D">Daniel</given-names></name><degrees>MA</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Abramson</surname><given-names initials="EL">Erika L</given-names></name><degrees>MD, MSc</degrees><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Navi</surname><given-names initials="BB">Babak B</given-names></name><degrees>MD, MS</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kamel</surname><given-names initials="H">Hooman</given-names></name><degrees>MD, MS</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Parikh</surname><given-names initials="NS">Neal S</given-names></name><degrees>MD, MS</degrees><xref rid="A1" ref-type="aff">1</xref></contrib></contrib-group><aff id="A1"><label>1</label>Clinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute and Department of Neurology, Weill Cornell Medicine, New York, NY, USA.</aff><aff id="A2"><label>2</label>Department of Pediatrics, Weill Cornell Medicine, New York, NY, USA.</aff><author-notes><corresp id="CR1"><underline>Correspondence</underline>: Neal S Parikh, MD, MS; 420 E 70<sup>th</sup> St, 4<sup>th</sup> Floor; New York, NY 10021. Telephone: 646-962-3829. Fax: 888-869-3929. <email>nsp2001@med.cornell.edu</email>.</corresp></author-notes><pub-date pub-type="ppub"><month>4</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>03</day><month>3</month><year>2023</year></pub-date><volume>54</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">432211</issue-id><fpage>992</fpage><lpage>1000</lpage><pub-history><event event-type="nihms-submitted"><date><day>07</day><month>03</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>01</day><month>04</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>01</day><month>04</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-15 05:25:25.783"><day>15</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1876500.pdf"/><abstract id="ABS1"><sec id="S1"><title>Background:</title><p id="P1">Smoking cessation rates after stroke and TIA are suboptimal, and smoking-cessation interventions are underutilized. We performed a cost-effectiveness analysis of smoking-cessation interventions in this population.</p></sec><sec id="S2"><title>Methods:</title><p id="P2">We constructed a decision tree and used Markov models that aimed to assess the cost effectiveness of varenicline, any pharmacotherapy with intensive counseling, and monetary incentives, compared to brief counseling alone in the secondary stroke prevention setting. Payer and societal costs of interventions and outcomes were modeled. The outcomes were recurrent stroke, myocardial infarction, and death using a lifetime horizon. Estimates and variance for the base case (35% cessation), costs and effectiveness of interventions, and outcome rates were imputed from the stroke literature. We calculated incremental cost-effectiveness ratios (ICER) and incremental net-monetary benefits (NMB). An intervention was considered cost effective if the ICER was less than the willingness-to-pay threshold of $100,000 per quality-adjusted life year (QALY) or when the incremental NMB was positive. Probabilistic Monte Carlo simulations modeled the impact of parameter uncertainty.</p></sec><sec id="S3"><title>Results:</title><p id="P3">From the payer perspective, varenicline and pharmacotherapy with intensive counseling were associated with more QALYs (0.67 and 1.00, respectively) at less total lifetime costs compared to brief counseling alone. Monetary incentives were associated with 0.71 more QALYs at an additional cost of $120 compared to brief counseling alone, yielding an ICER of $168/QALY. From the societal perspective, all three interventions provided more QALYs at less total costs compared to brief counseling alone. In 10,000 Monte Carlo simulations, all three smoking-cessation interventions were cost-effective in &gt;89% of runs.</p></sec><sec id="S4"><title>Conclusion:</title><p id="P4">For secondary stroke prevention, it is cost effective and potentially cost saving to deliver smoking cessation therapy beyond brief counseling alone.</p></sec></abstract><abstract id="ABS2" abstract-type="graphical"><title>Graphical Abstract</title><p id="P5">
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="nihms-1876500-f0001.jpg"/>
</p></abstract><kwd-group><kwd>smoking</kwd><kwd>secondary prevention</kwd><kwd>cerebrovascular disease/stroke</kwd></kwd-group><kwd-group><title>Subject Terms</title><kwd>Transient Ischemic Attack (TIA)</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>